Diabetisk ketoacidose etter immunterapi mot lungekreft
Engelsk titel: Diabetic ketoacidosis following immunotherapy for lung cancer
Läs online
Författare:
Skorpen, Per Kristian
;
Margull, Julia
Email: perkrskorpen@gmail.com
Språk: Nor
Antal referenser: 7
Dokumenttyp:
Fallbeskrivning
UI-nummer: 19050035
Sammanfattning
A man in his sixties was treated with pembrolizumab for non-small cell lung cancer and developed diabetic ketoacidosis. Pembrolizumab is a monoclonal antibody approved for treating several types of cancer. Diabetes mellitus type 1 is a rare adverse reaction to immunotherapy for cancer, and in the following we describe the first case reported in Norway of diabetic ketoacidosis resulting from this treatment.